157
Views
30
CrossRef citations to date
0
Altmetric
Review

The role of biosimilars in value-based oncology care

, , &
Pages 4591-4602 | Published online: 17 Oct 2018

Figures & data

Figure 1 US patent end of term dates for oncology mAbs and supportive care drugs.

Notes: *Biologic growth factors for the treatment of anemia or neutropenia due to myelosuppressive chemotherapy. Data from Generics and Biosimilars InitiativeCitation61 and Micklus.Citation103

Abbreviation: mAbs, monoclonal antibodies.

Figure 1 US patent end of term dates for oncology mAbs and supportive care drugs.Notes: *Biologic growth factors for the treatment of anemia or neutropenia due to myelosuppressive chemotherapy. Data from Generics and Biosimilars InitiativeCitation61 and Micklus.Citation103Abbreviation: mAbs, monoclonal antibodies.

Figure 2 Current and projected cost of cancer care in the USA by phase of care in 2010 and 2020, respectively, weighted to dollar values in 2010.

Note: Data from National Cancer Institute.Citation27

Figure 2 Current and projected cost of cancer care in the USA by phase of care in 2010 and 2020, respectively, weighted to dollar values in 2010.Note: Data from National Cancer Institute.Citation27

Figure 3 Commercial price comparison for short-acting G-CSFs (filgrastim-sndz, tbo-filgrastim, and filgrastim) based on the fourth quarter of 2017 (A) WAC/average wholesale price in the USACitation57 and (B) CMS payment limits (average sales price + 6%).Citation58

Abbreviations: AWP, average wholesale price; µg, microgram; CMS, Centers for Medicare & Medicaid Services; G-CSFs, granulocyte-colony stimulating factors; WAC, wholesale acquisition cost.

Figure 3 Commercial price comparison for short-acting G-CSFs (filgrastim-sndz, tbo-filgrastim, and filgrastim) based on the fourth quarter of 2017 (A) WAC/average wholesale price in the USACitation57 and (B) CMS payment limits (average sales price + 6%).Citation58Abbreviations: AWP, average wholesale price; µg, microgram; CMS, Centers for Medicare & Medicaid Services; G-CSFs, granulocyte-colony stimulating factors; WAC, wholesale acquisition cost.

Figure 4 OCM key drivers of cost reduction.

Figure 5 Range and weighted components of payments in the incentive payment program under the QPP.

Note: 2022 weighted components assumed, based on 2021 requirements.

Abbreviation: QPP, quality payment program.

Figure 5 Range and weighted components of payments in the incentive payment program under the QPP.Note: 2022 weighted components assumed, based on 2021 requirements.Abbreviation: QPP, quality payment program.

Notes: Data from Quality Payment Program, Centers for Medicare and Medicaid Services.Citation86 (A) Overview of payment programs under MACRA. (B) Overview of the Advanced Payment Models, including details on the OCM.

Abbreviations: APM, Alternative Payment Model; ACO, Accountable Care Organization; CEC, Comprehensive ESRD Care; CJR, Comprehensive Care for Joint Replacement; CPC+, Comprehensive Primary Care Plus; MACRA, Medicare Access and CHiP Reauthorization Act of 2015; MEOS, Monthly Enhanced Oncology Services; MIPS, Merit-based Incentive Payment System; OCM, Oncology Care Model; QPP, Quality Payment Program.

Figure 5 Range and weighted components of payments in the incentive payment program under the QPP.Note: 2022 weighted components assumed, based on 2021 requirements.Abbreviation: QPP, quality payment program.
Figure 4 OCM key drivers of cost reduction. Figure 5 Range and weighted components of payments in the incentive payment program under the QPP.Note: 2022 weighted components assumed, based on 2021 requirements.Abbreviation: QPP, quality payment program.Display full sizeNotes: Data from Quality Payment Program, Centers for Medicare and Medicaid Services.Citation86 (A) Overview of payment programs under MACRA. (B) Overview of the Advanced Payment Models, including details on the OCM.Abbreviations: APM, Alternative Payment Model; ACO, Accountable Care Organization; CEC, Comprehensive ESRD Care; CJR, Comprehensive Care for Joint Replacement; CPC+, Comprehensive Primary Care Plus; MACRA, Medicare Access and CHiP Reauthorization Act of 2015; MEOS, Monthly Enhanced Oncology Services; MIPS, Merit-based Incentive Payment System; OCM, Oncology Care Model; QPP, Quality Payment Program.

Figure 5 Range and weighted components of payments in the incentive payment program under the QPP.

Note: 2022 weighted components assumed, based on 2021 requirements.

Abbreviation: QPP, quality payment program.

Figure 5 Range and weighted components of payments in the incentive payment program under the QPP.Note: 2022 weighted components assumed, based on 2021 requirements.Abbreviation: QPP, quality payment program.